MYND Lifesciencs Inc
MYND Life Sciences Inc., a life sciences-based neuro-pharmaceutical drug development company, advances medicines based on neuro-anti-inflammatory substances for depressive disorders through science and clinical trials in Canada and the United States. It focuses on the analysis of psilocin and psilocybin extracts, and analogs. MYND Life Sciences Inc. is based in Port Coquitlam, Canada.
MYND Lifesciencs Inc (MYNDF) - Total Liabilities
Latest total liabilities as of July 2024: $6.71 Million USD
Based on the latest financial reports, MYND Lifesciencs Inc (MYNDF) has total liabilities worth $6.71 Million USD as of July 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
MYND Lifesciencs Inc - Total Liabilities Trend (2019–2023)
This chart illustrates how MYND Lifesciencs Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
MYND Lifesciencs Inc Competitors by Total Liabilities
The table below lists competitors of MYND Lifesciencs Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NIPPON MEAT PACKERS - Dusseldorf Stock Exchang
DU:NI6
|
Germany | €419.04 Billion |
|
Beeio Honey Ltd
TA:WTS
|
Israel | ILA1.62 Million |
|
Procaps Group S.A. Warrants
NASDAQ:PROCW
|
USA | $460.10 Million |
|
Fridenson
TA:FRDN
|
Israel | ILA146.91 Million |
|
INTL PAPER
BE:INP
|
Germany | €14.53 Billion |
|
J2 GLOBAL
MU:JXC1
|
Germany | €1.79 Billion |
|
OLVI -A- (OVI.SG)
STU:OVI
|
Germany | €209.39 Million |
|
MOBA Network publ AB
ST:MOBA
|
Sweden | Skr357.78 Million |
Liability Composition Analysis (2019–2023)
This chart breaks down MYND Lifesciencs Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 9.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MYND Lifesciencs Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MYND Lifesciencs Inc (2019–2023)
The table below shows the annual total liabilities of MYND Lifesciencs Inc from 2019 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-10-31 | $5.77 Million | +37.94% |
| 2022-10-31 | $4.19 Million | +52.87% |
| 2021-10-31 | $2.74 Million | +5000.56% |
| 2020-10-31 | $53.69K | +2838.59% |
| 2019-10-31 | $1.83K | -- |